Objective. The aim was to assess work-loss days before and after commencement of anti-TNF treatment in patients with non-radiographic axial spondylarthritis (nr-axSpA).
Introduction
Spondyloarthritis encapsulates a group of conditions with similar axial (sacroiliitis/spondylitis) and/or peripheral (arthritis/enthesitis/dactylitis) muskuloskeletal symptoms and an association with HLA-B27. While AS, the archetypal form of axial spondyloarthritis, is defined by radiographic sacroiliitis [1] , many patients display similar symptoms and sacroiliacal joint inflammation on MRI without such X-ray changes [2] . Therefore, in 2009, the Assessment of SpondyloArthritis international Society (ASAS) validated novel classification criteria for axial spondyloarthritis [3] , encompassing patients both with (AS) and without radiographic sacroiliitis; the latter group henceforth known as non-radiographic axial spondyloarthritis (nr-axSpA).
Studies comparing nr-axSpA and AS have found a similar burden of disease, and treatment recommendations are also alike [2, 410] . In AS, where proportions of work-disabled subjects range from 5 to 35% [11] , anti-TNF therapy has been repeatedly shown to improve work disability [1215] , whereas this has hitherto been very sparsely studied in nr-axSpA. In short-term randomized controlled trials, clinical response to either anti-TNF or placebo in nr-axSpA has been associated with favourable work-related outcomes [16, 17] . Significant anti-TNF effects on self-reported at-work productivity (presenteeism) have also been demonstrated, whereas results are less consistent regarding work-loss days (absenteeism) [18] . Results based on prospectively recorded register data are, however, lacking.
In the present study, we thus aimed to describe the development of work-loss days, attributable to sick leave and/or disability pension, in nr-axSpA from 1 year before to 2 years after anti-TNF initiation, and to compare this with matched population references. Predictors of work-loss days after anti-TNF start were also assessed.
Methods

Settings and data sources
Linkage of data from the following sources was accomplished using the personal identification number, unique to every Swedish citizen.
South Swedish Arthritis Treatment Group register
The South Swedish Arthritis Treatment Group (SSATG) register is an observational register study involving 12 rheumatology units, in which chronic arthritis patients commencing treatment with biologic DMARDs in southern Sweden were prospectively monitored according to a structured protocol starting in 1999 [19] .
Swedish Social Insurance Agency register and work disability compensation system
The Swedish Social Insurance Agency (SSIA) provides financial protection for individuals of working age (1664 years) in connection with sickness, disability or injury and covers everyone who legally lives or works in Sweden. Compensations are granted in the form of sick leave or, in the event of longstanding inability to work, disability pension, both of which may be granted for 25, 50, 75 or 100% of full working time, and the two compensation types may be combined in the same day (although never exceeding 100%; e.g. 25% disability pension and 75% sick leave).
For sick leave, the first day of absence (the qualifying day) is not compensated and days 214 are reimbursed by the employer. Short-term sick leave periods 4 14 days are thus not administered by the SSIA, whereas all workloss periods (sick leave and/or disability pension) exceeding 2 weeks are continuously and prospectively recorded in the SSIA register, from which day-level data on these compensations may be retrieved. Moreover, if a new sick leave period starts within 5 days of another, they are counted together, and once exceeding 14 days the first 2 weeks are also recorded in the SSIA register. In Sweden, it is also possible to be on sick leave as unemployed if you are considered unable to perform any kind of work on the labour market.
Swedish Population Register
The population register is a national register containing individual statistics of vital events such as births, deaths, marriages, divorces, migrations and residential addresses. The register is administrated by the Swedish Tax Agency.
Study population
Bionaïve nr-axSpA patients aged 1762 years, monitored at the Department of Rheumatology, Skå ne University Hospital and commencing anti-TNF treatment during 200411, were retrieved from the observational SSATG study (n = 75; patient inclusion flow chart provided in Fig. 1 ). All patients had a clinical diagnosis of undifferentiated axial spondyloarthritis and, based on retrospective analysis of data collected at anti-TNF initiation, fulfilled the ASAS criteria for axial spondyloarthritis, without skin psoriasis or radiographic sacroiliitis (n[ASAS criteria imaging/ clinical arms] = 43/32; modified New York criteria negative X-rays available for all; inflammatory sacroiliitis on MRI defined according to clinical practice) [1, 3] . In Sweden, anti-TNF agents were often used to treat patients with the nr-axSpA phenotype, even before this diagnosis was formally characterized in 2009, explaining the early treatment start dates in our cohort. For each patient, four population references matched for age, sex and municipality were randomly selected from the Swedish Population Register, in order to relate work-loss days in the nraxSpA group to the background population level and to control for secular trends.
Outcome variables
Day-level data on work-loss days attributable to sick leave and/or disability pension (excluding periods 4 14 days) for patients and population references were retrieved from the SSIA, covering 360 days before to 720 days after anti-TNF initiation (or for the references, the anti-TNF start date of their index patients) or until the individual www.rheumatology.oxfordjournals.org died. All work-loss days were included, irrespective of the cause; that is, for the patients, the recorded work disability could be related (directly or indirectly) or unrelated to nr-axSpA. The outcome variables studied were net days during each quarter of a year (90 days) of sick leave, disability pension and the combination of both (referred to as work-loss days). One net day corresponds to a full day of work-loss; for example, 4 days with 25% sick leave or 1 day with 75% disability pension and 25% sick leave.
Predictors of work-loss days from 6 months to 2 years after anti-TNF initiation in the nr-axSpA group were also studied, as described in the statistics subsection below.
Informed consent was given by all patients before entry in the SSATG register study. Cross-linking of SSIA and health-care data was approved by the ethical committee in Lund (no. 514/2007).
Exposures
Anti-TNF therapy was started because of high disease activity and inadequate response or intolerance to one or more NSAIDs. Treatment decisions were taken by the responsible rheumatologists, and no formal disease activity level was required for anti-TNF initiation, although the In comparison with the study population (n = 75), the 44 subjects with insufficient data for classification were significantly older [median (interquartile range; range) age: 47 (18; 2067) years] and had longer disease duration [11 (14; 142) years], whereas no difference was observed regarding sex, prior presence of peripheral arthritis, patient's VAS global/pain, BASDAI, BASFI, Evaluator's global, ESR or CRP scores at anti-TNF initiation (comparisons by 2 test for categorical and MannWhitney U-test for continuous variables). ASAS: Assessment of SpondyloArthritis international Society; nr-axSpA: non-radiographic axial spondyloarthritis; SSATG: South Swedish Arthritis Treatment Group; VAS: visual analog scale. indication was supported by guidelines when they began to emerge [9] . Apart from infliximab, which was started at 3 mg/kg, with possible dose increments to a maximum of 500 mg every 48 weeks, anti-TNF dosages were in general as recommended by the manufacturers. Patients could receive NSAIDs, low-dose oral glucocorticoids, intra-articular glucocorticoids and conventional DMARDs both prior to and during the study period according to clinical practice; the latter mainly applied for peripheral arthritis.
Statistics
Work-loss days
Owing to skewed distributions, the sick leave, disability pension and work-loss day levels between different follow-up periods within the nr-axSpA group were compared by the Wilcoxon matched-pair signed-rank test. Mean (95% CI) differences in the same outcomes between the nr-axSpA patients and population references were estimated by analysis of variance, accounting for the matched design and applying non-parametric bootstrapping to calculate CIs.
Predictor analyses
Predictors of cumulative net work-loss days (sick leave plus disability pension) from 6 months to 2 years after anti-TNF initiation (days 181720) in the nr-axSpA group were assessed by multivariate regression, using nonparametric bootstrapping to estimate CIs. Logistic regression with any work-loss days (n [yes/no] = 27/48) during the same period as outcome was also performed. The first 6 months following anti-TNF initiation was omitted from the outcome period, because we aimed to study predictors of future work-loss days rather than baseline associations (thus allowing 6 months for potential anti-TNF effects to stabilize).
The following potential predictors at anti-TNF initiation were identified based on subject matter knowledge: sex, age, disease duration, prior presence of peripheral arthritis (yes/no), inflammatory sacroiliitis on MRI (yes/no, defined according to clinical practice), CRP elevation (>3 mg/L; yes/no), anti-TNF start year (200411), net work-loss days during the final quarter before anti-TNF start (090 days) and scores of patient's visual analog scales for global health and pain (VAS global; VAS pain), evaluator's global assessment on a five-grade Likert scale (Evaluator's global), BASDAI and BASFI. Beyond these baseline variables, anti-TNF adherence 4 6 months (i.e. ceasing treatment prior to the outcome period) was also assessed.
Owing to the limited number of patients (n = 75), only the seven of these potential predictors with the highest Spearman correlation to the continuous outcome (i.e. cumulative net work-loss days) were included in the final models (applying the same variables in both the linear and logistic regressions). In the event of multicollinearity (Spearman's r 5 0.4 or À0.4 or less), the variable with the least correlation to the outcome was, however, omitted. Apart from this strategy, based on subject matter knowledge, we also decided to retain disease duration and CRP elevation in the analyses. When entering disease duration, age was omitted owing to multicollinearity, and with respect to the number of patients per covariate, the MRI variable (with the lowest correlation to the outcome of those originally included) was instead omitted when entering CRP elevation. All analyses were performed using International Business Machines Corporation's (IBM) Statistical Package for the Social Sciences (SPSS) version 20 or StataCorp's Stata version 13.1.
Results
Patient characteristics and anti-TNF adherence
Patient characteristics at anti-TNF initiation are presented in Table 1 . No patient died during the follow-up period. Allowing anti-TNF switches with 43 months from ceasing one agent to starting another, 72% of patients remained on anti-TNF therapy throughout the 2-year follow-up (60% on their initial treatment and 12% having switched once). By the same definition, the mean (S.D.) anti-TNF adherence time was 20 (7) months.
Work-loss days
In the year before anti-TNF initiation, the mean quarterly days of sick leave among the nr-axSpA patients increased significantly, peaking at 18.2 days more than among the population references in the quarter immediately after the start of treatment. Following anti-TNF initiation, the mean number of quarterly sick leave days then steadily (and significantly) declined during the 2-year follow-up, although remaining statistically higher than among the references throughout ( Fig. 2A) . Meanwhile, the disability pension level among the nr-axSpA patients did not differ from that of the population references at any time point (Fig. 2B) . Added together, during the 2 years from anti-TNF initiation, the mean quarterly number of work-loss days decreased significantly from a peak at 16.5 days to 6.8 days more than in the population references ( Figs 2C  and 3) .
As expected, the absence of any work-loss days from 6 months to 2 years after anti-TNF start was associated with consistently better point estimate means for clinical parameters during follow-up, as compared with patients with 51 work-loss day during the same period ( Table 2) .
Predictors of work-loss days after anti-TNF initiation
Higher work-loss day levels immediately before anti-TNF initiation and chronologically earlier anti-TNF start years significantly predicted more work-loss days during the outcome period (Table 3 ). In the logistic analysis, female sex, longer disease duration and, again, higher levels of baseline work-loss were associated with the occurance of any work-loss days during follow-up (Table 3) .
Discussion
Main findings
This population-based cohort study provides evidence of a significant and sustained decrease in sick leave among nr-axSpA patients after anti-TNF treatment initiation. Despite the improvement, however, the mean number of sick leave days still remained significantly higher than among the population references at the end of followup. In contrast, similar levels of disability pension were observed among the nr-axSpA patients and references throughout. Overall, during 2 years from anti-TNF initiation, the mean quarterly work-loss days in the nraxSpA group decreased from 3.4 to 1.9 times more than in the general population.
Previous research
Work-loss days
In a 6-month randomized controlled trial, etanercept treatment failed to show any impact on self-reported work- loss   FIG. 2 Developments of sick leave, disability pension and work-loss days Developments of mean (95% CI) days per quarter of a year (90 days) of sick leave (A), disability pension (B) and work-loss days (C) in the nr-axSpA group and population references from 1 year before to 2 years after anti-TNF initiation. The table below the graphs shows the mean (95% CI) difference in the respective outcomes between the nr-axSpA patients and references at key time points. *P < 0.05 and **P < 0.01 for change within the nr-axSpA group. Data for all 75 nr-axSpA patients were available for every quarter. One reference person died and did not contribute data for quarters 68. NraxSpA, non-radiographic axial spondyloarthritis; NS, non-significant. days, whereas presenteeism improved significantly more than with placebo [18] . In other short-term trials, both these outcomes have, however, been shown to improve more among clinical responders (vs non-responders) to either anti-TNF therapy or placebo, although less consistently so regarding work-loss days [16, 17] . Apart from this, data regarding work disability in nr-axSpA remain sparse [7] . In AS, in contrast, work-loss day levels are well known to exceed those of the general population [11, 20] , and several studies have demonstrated beneficial effects thereon of anti-TNF therapy [1215] . Comparing the present results with a previous AS study from the same region [14] , similar baseline levels and 1-year improvements of sick leave were observed, whereas disability pension was around four times more common among the AS patients, potentially reflecting the older age and more longstanding disease in this group [mean (S.D.) age, AS/ nr-axSpA: 41 (10)/37 (11) years; disease duration, AS/nraxSpA: 14 (11)/8 (8) 
Predictor analyses
Although previous data remain scant for nr-axSpA, a large number of factors have been associated with future work disability in patients with AS, with manual labour professions and worse scores for pain and physical disability (including BASFI) being among the most consistently reported [11] . In a recently published cohort study following AS patients for 12 years, adverse work outcomes were again predicted by higher BASFI scores at baseline, but also by worsening disease activity (BASDAI) and function (BASFI) over time, as well as by new occurrence of uveitis or IBD during follow-up [21] . Work disability in AS also Values are given as the mean (S.D.). Clinical parameters are shown in relationship to any work-loss day status from 6 months to 2 years after anti-TNF initiation in patients with non-radiographic axial spondylarthritis. No work-loss days, n = 48; work-loss days 51, n = 27. Number of work-loss days during the quarter of a year immediately before anti-TNF initiation. Missing data, n (%): disease duration 1 (1), MRI 9 (12) and CRP 4 (5). B: b estimate; OR: odds ratio.
www.rheumatology.oxfordjournals.org appears to increase with longer disease duration, although in relationship to age-matched population references the differences are most pronounced for younger patients [11] . With regard to sex, the available AS data are less consistent [11] . The finding that a higher level of baseline work-loss was associated with more (as well as any) work-loss days during follow-up was not unexpected and is supported by similar data from early RA, where this was identified as the strongest risk factor for more work-loss days during 3 years from diagnosis [22] . In analogy with this, worse levels of presenteeism have also been shown to predict future sick leave in patients with AS [23] . Whether an earlier anti-TNF intervention during the disease course of nr-axSpA would reduce future work-loss days cannot be concluded from the present data. The binary association observed with disease duration (although not controlled for age), as well as the better outcome seen in patients who have not already progressed to stages with more work-loss days before the start of treatment, may, however, both be interpreted to point in this direction. Finally, the observed association between anti-TNF start year and cumulative work-loss days is likely to reflect the stricter regulation of Swedish work disability compensations during later years, as well as a secular trend towards the use of anti-TNF therapy in less severely ill patients.
Strengths and limitations
The objective assessment of work-loss days by an external source, rather than self-reported questionnaires, is a major strength of the present study, which is, to our knowledge, also the first to demonstrate a significant and sustained impact of anti-TNF therapy on work-loss days in nr-axSpA.
Limitations encompass a lack of presenteeism data and the exclusion of sick leave periods 4 14 days, which are not recorded by the SSIA. The retrospective classification of patients according to the ASAS criteria for axial spondyloarthritis may have limited study inclusion, because all relevant data could not be retrieved for all the screened subjects (Fig. 1) . Furthermore, the open, observational setting naturally has limitations in its internal validity, such as possible bias regarding patients selected for treatment, assignment of treatment and collection of clinical data. The study outcomes were, however, collected from an independent and blinded source (the SSIA) for both patients and population references, and are of high quality because they are linked to the payment system.
Regarding the predictor analyses, the relatively low power (n = 75) may have limited our ability to demonstrate significant associations with some of the studied variables, whereas a lack of data prevented us from including other potential predictors, such as profession, co-morbidity status, presenteeism and coping strategies.
Conclusions
In patients with nr-axSpA, anti-TNF therapy was associated with a significant and sustained decrease in work-loss days during 2 years from treatment initiation. The decline was seen for sick leave, whereas disability pension rates remained similar to those of the general population throughout. Despite the decrease, the proportion of work-loss days was still twice as high as in the general population at the end of follow-up.
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